Denosumab for cancer-related bone loss
Author:
Affiliation:
1. Medical Oncology Department, Campus Bio-Medico University of Rome, Rome, Itlay
Publisher
Informa UK Limited
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1814731
Reference162 articles.
1. Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications
2. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
3. Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
4. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
5. Bone remodelling at a glance
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Bone complications of cancer treatment;Cancer Treatment Reviews;2024-11
2. Regulation of bone homeostasis: signaling pathways and therapeutic targets;MedComm;2024-07-24
3. Type 2 diabetes incidence in patients initiating denosumab or alendronate treatment: a primary care cohort study;Osteoporosis International;2024-07-24
4. Noncoding RNAs: the crucial role of programmed cell death in osteoporosis;Frontiers in Cell and Developmental Biology;2024-05-10
5. Circulating Tumour Cells in the Prediction of Bone Metastasis;Cancers;2024-01-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3